Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
can't you see I was kidding. I was doing my johnsotckpumper. Imagine, he starts a rumour on Yahoo and then come here and talk about that rumour.
Now, I will go on Yahoo and post there is a rumour of a great news today. See what I mean? Unfortunately, I don't know much about Viropro's future
Big news today. Buy at the opening
a big 5000$ of volume today...
you maybe right. But, if the rumour was real, you (or people having this information) would buy today
not much volume for a stock ready to explose
please provide a link of that rumour.
do you have Cynthia's contact info
If they were right, we would be at 0,05 at least
how did they evaluate it? I could say 1M or 100M and you coud not tell me I'm wrong
If you were Spectrum, would you deal with a company that could have problems with regulatories?
still no financials ahead.
From their website on march 21st: Whereas at the time, consolidating the BPD numbers proved longer because all prior accounting had been prepared on a cash basis, this time, the Alpha numbers are on accrual basis but produced according to IFRS and need translation to GAAP. This matter will be resolved shortly and once it is processed, normal flow of financials will resume.
Shortly means what?
exactly the kind of deal we want
Dr. Reddy’s Laboratories Ltd. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs).
The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.
The partnership with Merck Serono expands on Dr. Reddy’s presence in the biosimilar space in select emerging markets and enables participation globally.
G. V. Prasad, Vice-Chairman and CEO of Dr. Reddy’s Laboratories said, “We strongly believe that biosimilars is an important area of future growth and these products give us the opportunity to provide affordable and innovative medicines to patients across the globe. With the recent EMA and FDA guidance on biosimilars, it is clear that any significant player in the field will need strong biologics development, manufacturing and commercialization capabilities. Merck Serono’s and Dr. Reddy’s joint expertise in these fields makes for a powerful global partnership.”
“Our expertise in developing, manufacturing, and commercializing biopharmaceuticals gives us a clear advantage in the biosimilars field, and the partnership with Dr. Reddy’s will bring their first-in-market experience in biosimilars, as well as their expertise in generics and Emerging Markets, to the table,” added Stefan Oschmann, Chief Executive Officer of Merck Serono. “Sharing know-how, risks and rewards is the right approach to enter the emergent biosimilars market and will be a win-win for both parties. It further strengthens Merck Serono’s promise to live science and transform lives, by increasing access to quality medicines for patients, physicians and payers.”
The deal structure calls for Merck Serono and Dr. Reddy’s to co-develop the molecules included in the agreement. Dr. Reddy’s will lead early product development and complete Phase I development. Upon completion of Phase I, Merck Serono will take over manufacturing of the compounds and will lead Phase III development. The agreement is based on full R&D cost sharing.
Merck Serono will undertake commercialization globally, outside the US and with the exception of select emerging markets which will be co-exclusive or where Dr. Reddy’s maintains exclusive rights. Dr. Reddy’s will receive royalty payments from Merck Serono upon commercialization. In the US, the parties will co-commercialize the products on a profit-sharing basis. Additional terms of the deal were not disclosed.
Source: Dr.Reddy’s press release
maybe the calm before the storm
interesting reading
The American Pharmacists Association (APhA), National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) recently weighed in with the Food and Drug Administration (FDA) with recommendations to facilitate the entry of lower-cost products into the biologic and specialty pharmaceutical markets.
The pharmacy organizations have sent a joint letter to FDA as the agency works to finalize draft guidance related to the development of biosimilar products – less-expensive versions of complex biologic medicines that are determined to be highly similar or interchangeable. The FDA is working to implement the Biologics Price Competition and Innovation Act, which was enacted as part of the Affordable Care Act.
“Pharmacists are the most accessible healthcare professionals and recommending generic alternatives is a standard pharmacy practice,” the groups said in their letter to FDA. “Allowing pharmacists to perform fully within their scope of practice by permitting automatic substitution of cost-effective biologic and specialty medications increases availability, thereby greatly benefitting the entire health care system and the patients it serves.”
The joint letter offered the following recommendations for the FDA to consider:
Biosimilar products should maintain the same name as their reference biologic counterparts to help prevent confusion. The use of suffixes should be avoided as well.
Pharmacists should be able to automatically substitute biosimilar products for their biologic reference product, assuming the FDA deems interchangeability between products.
The FDA should provide further guidance regarding whether biosimilar medicines will be determined to be interchangeable with their reference products, how pharmacists can assess appropriateness of substitution for individual patients, labeling provisions for manufacturers, and prescribing standards for physicians.
An interchangeability reference list should be developed by the FDA, something similar to the current Orange Book for generics, to assist health care providers in managing these prescription orders.
“Our organizations recognize the need for education and training of health care providers on biosimilars,” APhA, NACDS and NCPA added in their letter. “Our organizations are willing to work with FDA and other stakeholders to help develop and provide education to pharmacists.”
how many?
So your guess is that a news is coming very soon and they have enough of 4M
on one day?
can't figure out why you have a 4M volume a day without news and that volume drop to 300k the day after. This is not a sell on news. There is no news. Someone can explain?
I wouldn't bet on it. We have had a lot of this possible exposure and nothing happened.
how many shares at 0,13? Millions?
with that kind of statement, you should be right! LOL!
late a little bit man.
Just found this from Spectrum. Great news for the use of Rituximab (rituxan). Is the confrimation of the deal with viropro closer? What is sure is Rituximab still alive for Spectrum
5/17/2012 7:32 AM ET
(RTTNews) - Spectrum Pharmaceuticals (SPPI: News ) announced the initiation of a Phase 2 study evaluating ZEVALIN Injection for intravenous use + rituximab in combination with motexafin gadolinium or MGd in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma. MGd is a redox modulating agent designed to selectively accumulate in cancer cells and interact with intracellular reducing metabolites, producing reactive oxygen species that can disrupt cell function and cause apoptosis.
The multicenter, randomized, open-label, Phase 2 study is designed to evaluate the safety and efficacy of the novel combination therapy. The study is designed to enroll a total of 100 patients in North America, who would be randomized to one of two treatment arms: ZEVALIN + rituximab, and MGd, or ZEVALIN + rituximab. The treatment period would be 10-12 days, followed by 12-week safety follow up and then up to 12-month follow up.
The primary endpoint is the complete response or CR rate within 6 months of study entry, while secondary endpoints consist of CR rate within 3 months, overall response rate within 6 months, and progression-free survival.
News with big impact. No trade since then. Are we halted?
IMO, when we get 0,02, should be at 0,04 very quickly. Something like one or two days
LOL! I said I might have to but still waiting. No volume, so no hurry
It looks like I will have to increade my bid. No one selling at 0,01 anymore. Don`t be surprised if you see 500k at 0,15 (or 2 X 250k)
i already own 1M plus of VPRO. I am quite sure of at least a five baggers but looking for a ten baggers. Ovesold and no volume is sign of great opportunity. No news does not always mean bad news
we're at 0,015
someone has market depth. Wanna know if I must buy on the ask or wait
finally grabbed 200k yesterday. Need 800k more. I`m patient. No hurry!
added 62k today. Let's continue. Still need 938k at 0,0101
I had the same question
you're right! There is not a high volume of trading also. The problem is there is no news but we all know that the value of VPRO even without Spectrum is a lot higher than 0,01.
We should be happy and see it as an opportunity to get much more. I added 450k this week and look to add 1M.
welcome back. It will be easier to me to follow you when you provide information although that was thin lately.
Great!
Wasn't you totally on the bid? isn't it?
perfect to me! You do what you said you were going to do. I respect that.